Health & Fitness
Tue, March 8, 2011Mon, March 7, 2011Sat, March 5, 2011Fri, March 4, 2011Thu, March 3, 2011Peregrine's Bavituximab HCV Abstract Accepted for Presentation at the 46th Annual Meeting of EASL
//health-fitness.news-articles.net/content/2011/ .. entation-at-the-46th-annual-meeting-of-easl.html
Published in Health and Fitness on Monday, March 7th 2011 at 5:10 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
TUSTIN, CA--(Marketwire - March 7, 2011) - Peregrine Pharmaceuticals, Inc. (
The abstract can be accessed through the EASL website [ http://www2.kenes.com/liver-congress/Pages/Home.aspx ]. In accordance with the EASL embargo policy, the accepted abstract titled "Escalating Repeat Dose Study of Bavituximab in Patients Co-infected with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus" (poster 1239) will be presented in a poster session on Saturday, April 2, 2011.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. ([ www.avidbio.com ]), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at [ www.peregrineinc.com ].